AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00002461
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00513474
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
Trial: NCT02975700
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day (400 mg in the morning and 600 mg in the evening)
Trial: NCT02416388
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11
Trial: NCT02416388
Drug: Mycophenolic acid (MPA)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GvHD prophylaxis post allogeneic SCT :~* 720 mg BID from D0 to D+28 for HLA-identical siblings~* 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors
Trial: NCT02784444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT01316900
Drug: GSK573719/GW642444 125/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125/25 mcg once-daily
Trial: NCT01316900
Drug: GSK573719/GW642444 62.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.5/26 mcg once-daily
Trial: NCT01316900
Drug: GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mcg once-daily
Trial: NCT02713841
Drug: inhaled human insulin (INH)
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant human insulin administered with Adagio-01 inhaler device
Trial: NCT00289900
Drug: MK-0524A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00289900
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02186171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection once a month.
Trial: NCT00954135
Drug: letrozolo+cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
Trial: NCT00954135
Drug: letrozolo+sorafenib+cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months
Trial: NCT01426555
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg IV single dose
Trial: NCT00834587
Drug: 5 mg/500 mg METAGLIP™ Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 5 mg/500 mg, single-dose non-fasting
Trial: NCT00513474
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
Trial: NCT02434614
Drug: Docetaxel,Cisplatin,Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
Trial: NCT00851136
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00851136
Drug: PRO95780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT03220555
Drug: EMLAPATCH (lidocaine, prilocaine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
Trial: NCT04098744
Drug: Placebo vaginal insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for artesunate vaginal inserts
Trial: NCT04597333
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone vaginal insert.
Trial: NCT02137356
Drug: standard dose capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
Trial: NCT01144351
Drug: ELND002
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01144351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01324466
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
Trial: NCT03517020
Drug: Forest Pharmaceuticals Inc's Bystolic Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03173508
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Trial: NCT00443287
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT03479346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Trial: NCT03949231
Drug: PD1/PDL1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
Trial: NCT01123525
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
Trial: NCT00657501
Drug: testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily transdermal gel, 300 mcg
Trial: NCT00657501
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily transdermal placebo gel
Trial: NCT01990352
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil will be administered intravenously at 30mg/m2 on days 1 of a 21 day cycle.
Trial: NCT01292473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied lyophilized in vials.
Trial: NCT03682393
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
Trial: NCT03682393
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
Trial: NCT01429935
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capsules of Ibuprofen 400 mg, every 6 hours for 5 days
Trial: NCT01881633
Drug: ISU302
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01881633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01433978
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.
Trial: NCT03395912
Drug: Intervention
RxNorm normalized name: DRESSING,QUIKCLOT INTERVENTION 1.5X1.5IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
Trial: NCT01296113
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~* Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~* Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total
Trial: NCT00440739
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 120 mg
Trial: NCT00440739
Drug: etoricoxib, flavoxate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 120 mg once and flavoxate 200 mg 3 times
Trial: NCT00440739
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once and placebo 3 times
Trial: NCT02551809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT04250363
Drug: Palcebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
Trial: NCT04250363
Drug: M5717 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 30 mg single oral dose of M5717 capsule on Day 1.
Trial: NCT04250363
Drug: M5717 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 60 mg single oral dose of M5717 capsule on Day 1.
Trial: NCT04250363
Drug: M5717 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 80 mg single oral dose of M5717 capsule on Day 1.
Trial: NCT04250363
Drug: M5717 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 100 mg single oral dose of M5717 capsule on Day 1.
Trial: NCT04250363
Drug: M5717 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 200 mg single oral dose of M5717 capsule on Day 1.
Trial: NCT04250363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
Trial: NCT04250363
Drug: M5717 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 60 mg single oral dose of M5717 capsule on Day 5.
Trial: NCT04250363
Drug: M5717 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 100 mg single oral dose of M5717 capsule on Day 5.
Trial: NCT04250363
Drug: M5717 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 200 mg single oral dose of M5717 capsule on Day 5.
Trial: NCT01857115
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04614779
Drug: CN128 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron chelator, oral tablets
Trial: NCT00949663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 1% human albumin in normal saline
Trial: NCT01401075
Drug: mistletoe extract
RxNorm normalized name: MISTLETOE EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
Trial: NCT03116087
Drug: Testosterone patch
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mcg testosterone patches or placebo applied twice weekly
Trial: NCT03116087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch
Trial: NCT04590183
Drug: Prednisolone Acetate 1% Oph Susp
RxNorm normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times a day
Trial: NCT00290758
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02681432
Drug: HIPEC
RxNorm normalized name: Hyperthermic Intraperitoneal Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
Trial: NCT03178942
Drug: Elimite™ Cream (permethrin) 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin Cream 5%
Trial: NCT01429623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00414609
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
Trial: NCT02203786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1.
Trial: NCT02256800
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: combined with 5-FU
Trial: NCT02559960
Drug: Breviscapine Powder-Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
Trial: NCT01681303
Drug: AST-120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02388568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Lifestyle Modification
Trial: NCT01795339
Drug: AZD3293
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT01795339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT03156621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo SC Q2W
Trial: NCT04598919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily by mouth for 24 weeks
Trial: NCT00649571
Drug: Doxycycline Monohydrate Tablets (100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fasting
Trial: NCT00649571
Drug: Adoxa Tablets 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fasting
Trial: NCT00094666
Drug: Comparator: placebo / Duration of Treatment - 6 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00395512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets.
Trial: NCT00483509
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
Trial: NCT01570192
Drug: Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
Trial: NCT04573907
Drug: Drug Levothyroxine 100 mcg
RxNorm normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of a 600 mcg levothyroxine dose
Trial: NCT04573907
Drug: Drug Eutirox 100 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a 600 mcg levothyroxine dose
Trial: NCT01091532
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given orally twice daily for 14 days
Trial: NCT01091532
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given orally, once on Days 1 \& 14, and twice daily on Days 3-13.
Trial: NCT02912520
Drug: Anti-Bacterial Agents
RxNorm normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of any antibiotic substance(s) over the course of 2 weeks
Trial: NCT03073304
Drug: Crystalloid based prime solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid based prime solution
Trial: NCT03073304
Drug: Erythrocyte based prime solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythrocyte based prime solution
Trial: NCT00576238
Drug: urea
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application twice daily for up to 6 months
Trial: NCT04576949
Drug: Cytisinicline
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Trial: NCT04576949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated oral tablets containing matched placebo
Trial: NCT03139253
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin 500 mg bid. for 14 days.
Trial: NCT03139253
Drug: tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tetracycline 750 mg bid. for 14 days.
Trial: NCT00624078
Drug: Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
Trial: NCT00003501
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT00744445
Drug: r-HuEPO
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
Trial: NCT00366535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tabs b.i.d.
Trial: NCT00366535
Drug: Neurotropin
RxNorm normalized name: neurotrophin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tabs b.i.d.
Trial: NCT03383133
Drug: SULT Allosteric Inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
Trial: NCT00725231
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
Trial: NCT00194090
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02594878
Drug: Pamidronatdinatrium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04495478
Drug: Placebo - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT04495478
Drug: Placebo - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04210115
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04210115
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT03004131
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no